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CLINICAL INVESTIGATION
IL-i receptor antagonist inhibits monocyte chemotactic peptide
1 generation by human mesangial cells
ZARIN BROWN, ROBERT M. STRIETER, Gu H. NEILD, ROBERT C. THOMPSON,
STEVEN L. KUNKEL, and JOHN WESTWICK
Department of Pharmacology, University of Bath, Avon, England, United Kingdom; Departments of Internal Medicine and Pathology,
University of Michigan, Ann Arbor, Michigan, USA; Department of Renal Medicine, Institute of Urology and Nephrology, University College
London, United Kingdom; Synergen, Inc., Boulder, Colorado, USA
IL-i receptor antagonist inhibits monocyte chemotactic peptide 1
generation by human mesangial cells. The elicitation of neutrophils and
monocytes from the circulation into the inflamed glomerulus is a key
process in the pathogenesis of proliferative glomerulonephritis. The aim
of this study was to determine the factors which regulate the expression
and synthesis of the monocyte specific chemotaxin, monocyte chemo-
tactic peptide 1 (MCP-1). Mesangial cells in culture did not constitu-
tively express MCP-l, but could be induced to express both MCP-l
mRNA and antigenic MCP-l by either stimulation with IL-la or TNFa,
which are also stimuli for interleukin 8 (IL-8/NAP-l) expression and
release. Pre-treatment of mesangial cells with the IL-l receptor antag-
onist (IL-Ira) induced dose-dependent inhibition of both the expression
of MCP-1 and IL-8 mRNA as well as the release of both chemotactic
peptides in response to IL-I a, while the receptor antagonist had no
significant effect on TNFa induced MCP-l and LL-8 generation. This
study demonstrates that the IL-I receptor antagonist was four times
more effective at inhibiting the IL- 1 induced expression and release of
IL-8 compared to that of MCP-1. These results suggest that mesangial
cell-derived MCP- 1 may play an important role in the recruitment of
monocytes in glomerular inflammation and that an IL-I receptor
antagonist may have therapeutic potential for the treatment of glomer-
ulonephritis.
The accumulation of polymorphonuclear leukocytes and
monocytes within the inflamed glomerulus, accompanied by
proliferation of resident mesangial cells and expansion of the
mesangial matrix are characteristic of immunologically-medi-
ated glomerulonephritis [1, 2]. The migration of inflammatory
cells into an extravascular site require a series of coordinated
signals, which include the generation of a chemotactic gradient
by the cells of the extravascular compartment. The nature of
the stimulus and the subsequent spectrum of chemotatic factors
produced, determine the specific leukocyte population elicited
to the inflammatory site [3]. This hypothesis is supported by the
recent characterization of a large family of structurally related
peptides which for the most part are potent chemotactic stimuli
with considerable target cell specificity [3, 4]. To date the best
characterized member of this family is interleukin-8, which is a
potent neutrophil chemotaxin [4].
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Mesangial cells on exposure to the pro-inflammatory cytok-
ines IL-la and TNFa express and release IL-8, as well as the
mesangioproliferative cytokine IL-6 [5—8]. These findings sup-
port the idea that the mesangial cell has an active role in the
propagation of inflammatory response within the glomerulus
and can no longer be considered as having a bystander role in
these events.
Another member of this family of chemotactic peptides is the
monocyte specific chemotaxin known as monocyte chemotactic
peptide 1 [3, 9]. We now report that human mesangial cells can
express MCP-l mRNA and release the MCP-1 peptide in
response to the same stimuli that induce the formation of IL-8
in mesangial cells, namely IL-la and TNFa. Since the most
potent stimulus for the induction and release of both IL-8 and
MCP-l was IL-l we have also examined the characteristics of
the IL-l receptors on mesangial cells which are coupled to the
generation of these chemotactic cytokines. The nature of the
receptors were identified pharmacologically by utilizing the
novel recombinant 17 kDa polypeptide IL-l receptor antago-
nist, which appears to have a higher affinity for type I, as
compared to the type II IL-i receptor on human cells [10, 11].
Methods
Materials
Human recombinant IL-la (specific activity 2.1 x io U/mI)
and human recombinant TNFa (specific activity of 6 x i07
U/mI), were gifts from Hoffman La Roche and Ernst-Boehr-
inger, respectively. The human recombinant IL-ira was sup-
plied by Synergen Inc. All culture reagents (endotoxin free) and
plastics were from Gibco and Nunc, respectively.
Mesangial cell preparation and culture conditions
Portions of macroscopically normal renal cortex were ob-
tained from human kidneys immediately after surgical nephrec-
tomy for renal carcinoma. Human MC were obtained from
glomeruli isolated by differential sieving and collagenase treat-
ment as described previously [51. Cell cultures were maintained
in Waymouth's MB752/l supplemented with 15% heat-inacti-
vated fetal calf serum, penicillin-steptomycin (10 U/mI and 10
g/ml) and fungizone [0.5 p.g/ml (complete MC-medium)]: all
cells in these studies were used between passages 2 and 6.
Mesangial cell identity was confirmed by using a series of cell
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Fig. 1. Expression of ,nesangial cell-derived MCP-1 mRNA in re-
sponse to IL-la and TNFa. A. Represents Northern blot analysis of
MCP-l mRNA by mesangial cells 6 hours postexposure to either
medium alone (1), IL-la (2) or TNFa (3). Laser densitometry of each
respective Northern blot panel B, (AU mm = is the actual absorbance
of the density of the autoradiograph for each of the bands of mRNA
determined by the laser per mm), and C, 28S and 18S ribosomal RNA
demonstrating equal loading of RNA. These results are representative
of three experiments.
ng/mI ng/mI
Fig. 2. Dose-dependent induction of MCP-1 generation by IL-I a and
TNFa-siimulated mesangial cells. Antigenic MCP-1 levels were deter-
mined by ELISA following 18 hours stimulation with appropriate dose
of IL-la (0.03 to 10 ng/ml), TNFa (30 to 1000 nglml) or medium control,
Data shown are from a representative experiment, similar results were
obtained in three other experiments (all experiments were performed in
duplicate). Results are the mean SCM of quadruplet samples.
Extracellular IL-8 activity of culture supernatants was mea-
sured using a double-ligand ELISA method [14]. The detection
limit of this assay is 50 pg/mI. Anti-human IL-8 mouse mono-
clonal antibody, human recombinant IL-8 and anti-human IL-8
goat polyclonal antibody conjugated to alkaline phosphatase
were supplied by Sandoz, Vienna, Austria. The substrate
p-nitrophenyl phosphate (Sigma) was dissolved in 10% dieth-
anolamine buffer pH 9.8 to a final concentration of 1 mg/mI. The
reaction was stopped with 50 pd/well of 3 M NaOH when the
desired extinction had been reached.
markers according to the method described previously [5]. In
addition, MC displayed the characteristic hillock structures in
culture as described by Sterzel et al [121. Electron microscopy
of cell cultures revealed the presence of prominent bundles of
peripheral microfilaments with focal attachment bodies (dense
bodies) along their course, a feature which is associated with
mesangial and smooth muscle cells and is absent in fibroblasts
[131.
Experimental protocol
For experiments MC (5 x l05/well) were plated on to gelatin
coated 24-macrowell tissue culture plates and 80 cm2 tissue
culture flasks (for Northern blots). Twenty-four hours before
stimulation confluent cell cultures were washed and cultured in
serum-free medium (without fetal calf serum or growth factors).
Growth arrested cultures were pre-treated with the appropriate
Northern blot analysis
Total cellular RNA from mesangial cells was isolated using a
modification of the method of Chirgwin et al and Jonas, Sargent
and Davis [15, 16]. RNA from MC was extracted and separated
by Northern blot analysis using the method described by
Strieter et al [171. Briefly, mesangial cells were solubilised in a
solution consisting of 25 mrt Tris, pH 8.0 containing 4.2 M
guanidine isothiocyanate, 0.5% Sarkosyl and 0.1 s4 2-mercap-
toethanol. After homogenization, the above suspension was
added to an equal volume of 100 mM Tris pH 8.0 containing 10
mM EDTA and 1% SDS. The RNA was then extracted with
chloroform-phenol and chloroform-isoamyl alcohol. The RNA
was alcohol-precipitated and the pellet dissolved in 10 mM Tris,
0.1 mr's EDTA buffer with 0.1% Sarkosyl. The concentration of
RNA was determined by obtaining the absorbance at A260 and
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dose of IL-ira (10 to 1000 ng/ml) or media control for 15 minutes
at 37°C, before the addition of sub-maximal concentration of
either IL-la (6 ng/ml) or TNFa (300 ng/ml), which were
selected from previous dose-response studies [5]. Cultures were
incubated for a further 18 hours for quantitation of extracellular
MCP-1 and IL-8. Expression of mRNA for both peptides was
determined by Northern blot analysis six hours post-stimulation
with either cytokine.
Enzyme-linked immunoadsorbent assay (ELISA) for IL-S
IL
-I 
R
e 
(10
00
 ng
/m
I)i 
_
_
_
_
_
 
Li
sa
 (30
0 n
g/
m
III
 
+
tL
-1
R
a 
(10
0 n
g/
m
I)I 
ía
 
IL
-i H
a 
(30
 n
g/
m
I) 
P 
IL
-iR
a 
(10
 n
g/
m
I) 
I 
a
 
IL
-iR
a 
(10
00
 ng
/m
I) 
a
 
IL
-i 
(3 
n
g/
m
I)I 
$ 
IL
-iR
a 
$ 
—
i 
I 
(10
00
 n
g/
m
I) 
I1
-1
a 
(30
0 
n
g/
m
I)] 
LI
 
o
IIL
-1
R
a 
(10
0 n
g/
m
I) 
01
 
U 
=
1 I 
IL
-iR
a 
(30
 n
g/
m
I) 
$ 
0 
—
 
[IL
-iR
a (1
0 
n
g/
m
I) 
$ 
TN
F(
30
0n
g/m
I) 
$ 
A
100
z 80
60O(
B q-E
40
P
Brown et al: IL-i receptor antagonist inhibits MCP-i generation 97
MCP-1 mRNA
-1 8s
Fig. 3. Effect of IL-i receptor antagonist on
MCP-i mRNA expression by mesangial cells
in response to IL-ia or TNFa. Cells were pre-
treated with the appropriate dose of IL-ira for
15 minutes, before the addition of either IL-I a
or TNFa. Total RNA was extracted five
hours post-challenge. A. Northern blot of the
MCP-1 mRNA expression, laser densitometry
of each respective Northern blot panel B, and
28S and l8S ribosomal RNA panel C. These
results are representative of three
experiments.
A280 nm, so that 10 g of RNA was loaded into each well of the
agarose gel. RNA was separated by Northern blot analysis
using formaldehyde, 1% agarose gels, and transblotted to
nitrocellulose. The blots were baked under vacuum, prehybrid-
ized, and then hybridized with a 32P 5'-end labeled oligonucle-
otide probe. The 30 mer oligonucleotide probes were comple-
mentary to either nucleotides 262-291 or nucleotides 256-285 of
published cDNA sequence for IL-8 and MCP-1, respectively
[18, 19]. The sequence of the IL-8 probe was 5'-GTT-GGC-
GCA-GTG-TGG-TCC-ACT-CTC-AAT-CAC-3' [18], while the
sequence for the MCP-l probe was 5'-TTG-GGT-TTG-CTT-
GTC-CAG-GTG-GTC-CAT-GGA-3' [19]. Blots were quanti-
tated by laser densitometry [171. Equivalent amounts of total
RNA load per gel lane were assessed by monitoring 18S and 28S
RNA.
Enzyme-linked immunoadsorbent assay for MCP-I
Antigenic MCP-l was measured using a double-ligand
method, as previously described [20]. In brief, 96-well ELISA
plates (Nunc-Immuno Maxisorb plate, Gibco Ltd) were coated
with 50 p1/well of rabbit anti-MCP- 1 (3.2 jsg/ml) in coating
buffer (borate-buffered saline, 50 ms's H3B01, 120 ms's NaC1, pH
8.6) and incubated overnight at 4°C. The plates were washed
three times with 200 xl/well of wash buffer [phosphate-buffered
saline (PBS) + 0.5% vol/vol Tween 201. Nonspecific binding
sites were blocked with 2% bovine serum albumin in PBS and
incubated for one hour at 37°C. Plates were washed three times
with wash buffer, followed by the addition of 50 p1/well in
duplicate of either MCP-l standards (1-1000 pg/mi diluted in
wash buffer supplemented with 2% FCS), or culture superna-
tants (neat, 1:5, and 1:10), incubated for one hour at 37°C.
Plates were washed three times with wash buffer, and 50 p1/well
of biotinylated rabbit anti-MCP-1 (6 j.g/m1 in PBS + 2% FCS)
was added for 45 minutes at 37°C. Plates were washed three
times, followed by the addition of 100 p1/well of 1:5000 avidin-
horseradish peroxidase (Dako Ltd) diluted in wash buffer + 2%
FCS, and incubated for 30 minutes at 37°C. Following three
washes, a 100 p1/well of the chromogen substrate (0.67 mg/ml
C
F 
IL
-iR
a 
(10
00
 n
g/
m
I) 
IL
-i 
H
a 
(30
0 n
g/
m
I)I 
(9 
+
 
IL
-iR
a 
(10
0 
n
g/
m
I) 
IL
-iR
a 
(30
 n
g/
m
I) 
IL
-iR
a 
(10
 n
g/
m
I) 
IL
-iR
a 
(10
00
 ng
/m
I) 
IL
-i 
(3 
n
g/
m
I) 
_
 
IL
-iR
a 
(10
00
 ng
/m
I) 
z I 
IL
-iR
a 
(30
0 n
g/
m
I) 
+
 
IL
-iR
a 
(10
0 n
g/
m
I) 
IL
-iR
a 
(30
 ng
/m
l) 
IL
-i 
R
a 
(10
 n
g/
m
 I) 
TN
E 
(30
0 n
g/
m
I) 
100
zE 80
C
60
BO
40E
20
a,
a, 0
orthophenylenediamine dichioride in 25 m citrate/phosphate
pH 5.0, and 0.0002% hydrogen peroxide) was added and the
plates were incubated at room temperature until color develop-
ment was noted, at which point the reaction was terminated
with 50 id/well of 3 M H2S04. The absorbance was read at 490
nm in an ELISA plate reader.
Results
MCP-1 expression in mesangial cells
We examined the expression of MCP-l mRNA transcripts in
mesangial cells by Northern blot analysis. Figure 1 shows that
mesangial cells did not express detectable amounts of MCP-l
mRNA, after six hours in medium alone (Fig. IA and B).
However, after six hours of exposure to either IL-I a (6 ng/ml)
or TNFa (300 ng/ml), significant induction in the expression of
MCP-1 mRNA was observed with both cytokines (Fig. lA and
B).
MCP-1 peptide synthesis and release by mesangial cells
Figure 2 shows that supernatants derived from MC cultured
in the presence of serum-free medium alone did not contain
detectable levels (<50 pg/mi) of MCP-l at 18 hours. While the
Fig. 4. Effect of iL-i receptor antagonist on
IL-8 mRNA expression by mesangial cells in
response to iL-ice or TNFa. Cells were pre-
treated with the appropriate dose of IL-ira for
15 minutes, before the addition of either IL-la
or TNFa. Total RNA was extracted five
hours post-challenge. A. Represents the
Northern blot of the IL-8 mRNA expression,
laser densitometry of each respective
Northern blot panel B, and 28S and 18S
ribosomal RNA panel C. These results are
representative of three experiments.
addition of IL-la (0.3 to 30 ng/ml) or TNFa (30 to 1000 nglml)
for 18 hours resulted in a dose-dependent release of MCP-1
peptide from mesangial cells (Fig. 2).
Effect of IL-i receptor antagonist on cytokine induced MCP-i
and IL-8 mRNA expression of mesangial cells
Having demonstrated that IL-i a was the most potent stimuli
for the generation of MCP-1 and IL-8 from mesangial cells, we
next wanted to determine the nature of IL-i receptor coupled to
their synthesis. Pre-treatment with the IL-ira (10 to 1000 ng/ml)
for 15 minutes followed by five hours exposure to either IL-la
(3 ng/ml) or TNFa (300 ng/ml) resulted in dose-dependent
inhibition of only the IL-l induced expression of MCP-1 mRNA
(Fig. 3A and B), with complete inhibition of MCP-l mRNA
transcripts being achieved with a dose of 100 nglmi of IL-ira. In
marked contrast, the TNFa induced MCP-l mRNA expression
was unaffected by the IL-ira in the dose range of 10 to 1000
ng/ml (Fig. 3A and B). The IL- lra in this concentration range
did not exhibit any agonist effects (Fig. 3A and B). Similarly
expression of the neutrophil chemotactic peptide IL-8 mRNA
transcripts induced by IL-la was effectively antagonized by
IL-ira. Complete inhibition of IL-8 mRNA expression was
98 Brown et a!: IL-i receptor antagonist inhibits MCP-I generation
IL-8 mRNA
A -18s
C
-
a
 
-
a
 
a
 
-
a
 
0 
N
J 
a
 
a
, 
0 
N
J 
a
 
0 
N
J 
a
 
0 
w
 
0 
N
-) 
a
 
C •0 (a)
 0 0 0 0 0 
fl Cs) S cO 3 
r r
 
-
f-_
s a,
 
L.
 
N
JN
JN
JN
J 
0 N
J 
a
 C
) C
) 0
 
a
 0
) 0
) 0
 NJ 
a
 a
 
IL
-8
, n
g/
m
i 
IL
-B
, n
g/
m
I 
w
 
a
 -a
 N
J 
N
J 
(0 
w
 a
 a
 0
10
1 
C)
 
00
10
01
0C
)10
CJ
10
01
00
1 
0 
I:-
 
(A
) 5+
 
cO
 3 
0 0 (0 0 0 0 0 0 S Co 3 
I 
a0
I
0
Brown et a!: IL-i receptor antagonist inhibits MCP-i generation 99
L +
TNF (300 ng/mI)
Fig. 5. Effects of IL-i receptor antagonist on cytokine-induced release
of extracellular MCP-i by mesangial cells. Cells were pre-treated with
the appropriate dose of IL-Ira for 15 minutes with IL-ira, before the
addition of either IL-I a (A) or TNFa (B), cultures were incubated for a
further 18 hours and supernatants were quantitated for extracellular
MCP-l activity. Data shown are from a representative experiment.
Similar results were obtained in four other experiments (all experiments
were carried out in duplicate). Results are the mean SEM ofquadru-
plet samples.
observed with a dose of 30 ng/ml of IL-ira (Fig. 4A and B). The
TNFa induced IL-8 mRNA expression was unaffected by the
IL-ira at all concentrations used (10 to 1000 ng/ml; Fig. 4A and
B).
Effect of IL-i receptor antagonist on cytokine-induced MCP-i
and IL-8 synthesis and release by mesangial cells
Treatment of mesangial cells with either IL-Ia (3 ng/ml) or
TNFa (300 ng/ml) for 18 hours induced significant generation of
MCP-i peptide, with a concentration range of 12 ng/mI and 9.7
nglml, respectively, compared with unstimulated controls (Fig.
5A and B). Pre-treatment of mesangial cells for 15 minutes with
IL-ira (10 to 1000 ng/ml), resulted in dose-dependent inhibition
of IL-la(3 ng/ml) induced release of MCP-l (Fig. 5A), whereas,
release of this peptide was unchanged in response to TNFa (300
nglml; Fig. SB). Similarly, the IL-la induced release of IL-8,
resulted in dose-dependent inhibition by the IL-lra, while the
TNF (300 ng/mI)
Fig. 6. Effect of IL-i receptor antagonist on cytokine-induced release
of ext racellular IL-8 by mesangial cells. Cells were treated as described
in Figure 5. Supernatants were quantitated for extracellular IL-8
activity. The IL-la or TNFa induced release of extracellular IL-8 in the
presence or absence of the IL-lra are shown in A and B, respectively.
Data shown are from a representative experiment. Similar results were
obtained in four other experiments (all experiments were carried out in
duplicate). Results are the mean SEM of quadruplet samples.
receptor antagonist had no significant effect on TNFa induced
IL-8 release (Fig. 6A and B). The IL-ira was a more effective
antagonist of IL-la induced IL-8 release (IC50 12 ng/ml) than
MCP-1 release (IC50 54 ng/ml) in mesangial cells. Thus the
receptor antagonist was four times more effective at blocking
IL-8 than MCP-1 release from mesangial cells.
Discussion
We have demonstrated that cultured human mesangial cells,
upon stimulation with either IL- 1 a or TNFa, release significant
quantities of MCP-l peptide, which is a potent monocyte
specific chemotaxin [3]. These results, together with our earlier
observations that mesangial cells release the neutrophil chemo-
taxin, IL-8 [5—8], suggest that mesangial cells have the potential
for directing the specific leukocyte population within the gb-
merulus, a feature which is associated with different forms of
immunologically mediated glomerulonephritis [1, 2]. Interest-
ingly, under our experimental conditions, the mesangial cells
IL-iRa L IL-lila+
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displayed a differential synthesis of the two chemotactic pep-
tides, with two- or threefold more IL-8 than MCP- I being
released in response to IL-i. Whether such quantitative differ-
ences in chemotactic cytokine generation by mesangial cells
accounts for the time dependent elicitation of various leuko-
cytes within the glomeruli in vivo, is at present unknown.
However, the mesangial cell clearly has the potential, by
differential regulation of IL-8 and MCP- 1 generation, to dictate
which population of leukocytes are enriched within the glomer-
uli. At present very little information is available concerning the
nature of the signal transduction system involved in the gener-
ation of these chemotactic peptides and thus targets for thera-
peutic intervention are limited.
The participation of infiltrating monocytes in the pathogene-
sis of human proliferative glomerulonephritis has been recog-
nized for some time [21]. The monocyte has been regarded as a
source of procoagulant activity, pro-inflammatory mediators,
and matrix degrading enzymes [1, 22]. The accumulation of
activated macrophages would provide a positive feedback
mechanism via the macrophage derived IL-i and TNF which
would activate the mesangial cells to generate more of the
monocyte chemotaxin. Clearly there must be a number of
signals which regulate this destructive cycle of events.
To examine this possibility, we have explored the potential of
a recombinant form of IL-i receptor antagonist, which was
originally isolated from IgG stimulated macrophages [11]. Our
present results indicate that the IL-I receptor antagonist effec-
tively inhibit, in a dose-dependent manner, IL-la but not TNFa
induced MCP-l and IL-8 mRNA expression and peptide re-
lease. Studies with IL-ira in other cells demonstrate that
approximately 100- to 300-fold excess of IL-lra is required to
produce a 50% inhibition of IL-I induced response [23, 24].
However, mesangial cells only require a threefold excess of
IL-ira to block IL-l induced chemotactic cytokine generation.
These results indicate that mesangial cells express low numbers
of high affinity IL-i receptors. The data also shows that
although the IL-la induced response for both chemotactic
peptides was inhibited by IL-ira, the antagonist was four times
more effective at inhibiting the expression and release of IL-8
than MCP-1.
Recent reports indicate that the IL-ira blocks the binding of
IL-I to human cells bearing both type I and II receptors, but
one requires 10- to 50-fold more antagonist to block the type II
receptors [23]. The difference in potency of IL-Ira in blocking
the IL-i type I or II receptors on human cells may be one
explanation for our observed difference in blockade of MCP-l
and IL-8 response induced by IL-la in mesangial cells. The
results of this study suggest that the mesangial cell may possess
both types of receptors for IL-i, such that the signal for IL-I
induced IL-8 response may be operating via the type I receptor,
whereas the signal for IL-i induced MCP-l response requires
either one (type II receptors only) or both types of receptors.
Alternatively, there may be associated accessory binding or
signaling proteins on mesangial cells which are different for
MCP-l and IL-8.
Several studies have identified that mesangial cells in re-
sponse to IL-l, can proliferate as well as synthesize and release
other inflammatory mediators [25, 26]. Thus the inhibition of
IL-l action within the inflamed glomerulus is a potential target
for the therapeutic control of glomerulonephritis. Glucocorti-
coids such as dexamethasone are effective inhibitors of IL-i
induced cytokine generation by fibroblasts and macrophages
[27, 28], however, dexamethasone does not inhibit IL-i-in-
duced IL-8 generation by mesangial cells [5]. In this study we
demonstrate the ability of the recombinant IL-ira to effectively
block IL-I induced generation of both ehernotaxins, MCP-i and
IL-8. Thus the results of this study suggest that the IL-l
receptor antagonist may have therapeutic potential for the
treatment of glomerulonephritis.
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